Article

U.S. Rep. Dan Meuser announced that nine major pharmaceutical companies, including Amgen and Merck, have agreed to Most Favored Nation (MFN) pricing, following President Trump's executive order aimed at reducing U.S. prescription drug costs.

This brings total participation to 14 of the 17 largest global drug manufacturers. The MFN pricing system, effective January 2026, is expected to provide approximately $12 billion in annual savings and will impact Medicare, Medicaid, and uninsured patients.

Significant price reductions for drugs like Plavix and insulin are also expected. Additionally, the agreements involve over $150 billion in U.S. manufacturing investments. Separately, the Pennsylvania House passed legislation ensuring vaccine access through pharmacists amidst federal policy changes, while U.S.

Sen. Dave McCormick supported key provisions in the National Defense Authorization Act for Fiscal Year 2026 to enhance military readiness and infrastructure in Pennsylvania.